We conducted a population-based case-control study where the cases were children with a first episode of acute CNS inflammatory demyelination in France…
When the analysis was restricted to subjects compliant with vaccination, HB vaccine exposure >3 years before index date was associated with an increased trend… essentially from the Engerix B vaccine…
The OR [odds ratio] was particularly elevated for this [vaccine] in patients with confirmed multiple sclerosis.
[T]he Engerix B vaccine appears to increase [the risk of CNS inflammatory demyelination in childhood], particularly for confirmed multiple sclerosis, in the longer term.